Best Life Sciences Tech Companies in Toronto, Canada
The 63 best Life Sciences Tech companies in Toronto, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Deep Genomics.
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Tech companies in Toronto
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Deep Genomics AI-powered platform for RNA biology to accelerate genetic therapy discovery 55AI top 22%Moat top 28%Funding top 29%Patents top 33% All 11 signals ▾AItop 22% Moattop 28% Fundingtop 29% Patentstop 33% Innovationtop 39% Talenttop 41% Marketbottom 49% Globalbottom 43% Techbottom 37% Growthbottom 35% Newsbottom 27% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Moat: Editorial + unicorn rating 8/10 · IP moat: 92 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $238M | 58 mo ago | Series C | Brendan Frey Co-Founder & Chief Innovation Officer | 2014 | WagtailPythonDjango+9 | 92 patents Patents concentrated in chemistry & materials | 6 job openings · 1 expansion |
| 2 | Benchsci Developer of an AI platform for understanding disease biology 78AI top 20%Funding top 25%Talent top 28%Moat top 31% All 11 signals ▾AItop 20% Fundingtop 25% Talenttop 28% Moattop 31% Techtop 32% Innovationtop 35% Producttop 37% Markettop 45% Growthtop 45% Globalbottom 37% Newsbottom 32% AI: Classified as an AI company Funding: Raised $170M across 7 rounds · 7 rounds over 10 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $170M | 37 mo ago | Series D | Elvis Wianda Co-Founder | 2015 | HubSpot CMS HubSalesforceFacebook Login+20 | — | 1 launch |
| 3 | ACTO Provider of an AI and SaaS-based educational platform for the life science industry 40Funding top 29%Growth top 37%Moat top 39%Product top 40% All 7 signals ▾Fundingtop 29% Growthtop 37% Moattop 39% Producttop 40% Techtop 48% Globalbottom 43% Marketbottom 29% Funding: Raised $39.5M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $40M | 21 mo ago | Series B | — | 2014 | WordPressMySQLPHP+28 | — | — |
| 4 | Cyclica AI platform for supporting drug discovery research | $21M | 43 mo ago | Acquired | Jason Mitakidis Founder | 2013 | — | 32 patents AI-driven computational drug discovery and proteome-wide ligand docking platforms | — |
| 5 | Intrepid Labs Developer of drug formulation science to accelerate the development of therapeutics 35Market bottom 49%Funding bottom 49%Talent bottom 49%Global bottom 45% All 4 signals ▾Marketbottom 49% Fundingbottom 49% Talentbottom 49% Globalbottom 45% Funding: Raised $11.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $11M | 13 mo ago | Seed | Christine Allen Co-Founder and CEO | 2023 | — | — | — |
| 6 | Pathcore A secure, browser-based platform for managing your digital pathology and radiology images | $10M | 123 mo ago | Funding Raised | — | 2006 | WebflowZohojQuery+7 | 6 patents Monitoring tissue exposure to treatment media in medical diagnostic/therapeutic devices | 1 job opening |
| 7 | Phenomic AI Developer of deep learning based tools for drug discovery | $8M | 68 mo ago | Seed | Sam Cooper Co-Founder & CEO | 2017 | BootstrapApache HTTP ServerAmazon Web Services+8 | 28 patents Immunotherapy targeting CTHRC1 via antibodies, fusion proteins, and T‑cell engagers | — |
| 8 | PharmaTher Provider of AI-based platform for repurposing psychedelic drugs | $8M | 57 mo ago | Public | Fabio Chianelli CEO | 2020 | WeeblyMySQLPHP+17 | — | — |
| 9 | ProteinQure Provider of computational protein drug design platform 53Talent top 28%AI top 30%Innovation top 36%Product top 36% All 10 signals ▾Talenttop 28% AItop 30% Innovationtop 36% Producttop 36% Moattop 37% Patentstop 38% Fundingtop 46% Techbottom 45% Globalbottom 40% Marketbottom 29% Talent: Analyst team rating 4/5 · 4 named leaders on record AI: Classified as an AI company · Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 53/100 | $4M | 12 mo ago | Series A | Tomas Babej Cofounder and Chief Technology Officer | 2017 | WordPressProton MailApple iCloud Mail+13 | 9 patents Targeted peptide therapeutics delivering payloads via sortilin and NPR‑C receptor pathways | 2 job openings |
| 10 | Ranomics Database of rare genetic variants | $1M | 117 mo ago | Seed | — | 2015 | WixSentryBootstrap+17 | 7 patents High-throughput multisite saturation mutagenesis and splice‑junction variant analysis for gene engineering | — |
| 11 | Clincove AI-powered clinical trial management platform designed to streamline and accelerate Phase I–III studies 40AI top 45%Talent top 45%Funding bottom 41%Global bottom 33% All 4 signals ▾AItop 45% Talenttop 45% Fundingbottom 41% Globalbottom 33% AI: Product described with: ai-powered Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 40/100 | $500K | 8 mo ago | Seed | Michael Sousa Chief Technology Officer | 2023 | — | — | 2 launchs |
| 12 | Advanced Chemistry Development Labs Cheminformatics system | $245K | 61 mo ago | Acquired | — | 1994 | Cart FunctionalityWooCommerceWordPress+34 | — | 1 launch |
| 13 | A.I. VALI Inc AI-based clinical image analysis and reporting tool | $189K | 34 mo ago | Seed | Azar Azad Founder | 2017 | — | 5 patents Real-time processing of medical and endoscopic imaging data | 2 awards |
Top 12 Life Sciences Tech companies in Toronto
#1
Seed · Toronto, Ontario · founded 2023$11Mraised▾
Developer of drug formulation science to accelerate the development of therapeutics. The proprietary technology platform, VALIANT, enables the design and optimization of fully optimized formulations of drugs by improving the properties and performance of therapeutic molecules.
- May 2025Seed$7M
- 2023Seed$4M
#2
Series B · Toronto, Ontario · founded 2014 · 18 employees$39.5Mraised▾
Provider of an AI and SaaS-based educational platform for the life science industry. The company has developed a digital platform with learning tools like SALESFitness which is a product that provides trading in clinical sales, MARKETINGFitness a centralized tool for life science marketing of new launches, MSLFitness provides engaging learning experiences and more. There are features for remote video coaching, user engagement tools, and AI-assisted tools for performance tracking.
- Sep 2024Series B$10M
- Jul 2022Series B$18M
- Aug 2020Series A$11.5M
#3
Series A · Toronto, Ontario · founded 2017 · 18 employees$4Mraised▾
Provider of computational protein drug design platform. It predicts the protein folds using hybrid quantum algorithms and performs molecular simulations on GPU superclusters. It designs peptide-based therapeutics using quantum computing, artificial intelligence, and molecular dynamics simulations. Additionally, it uses AlphaGo to train a model and impart reinforced learning which facilitates protein drug designing. It claims to have multiple features including more binding sites, fewer side effects, and easy synthesizing and lab testing.
- May 2025Series A$11M
- Feb 2024Seed—
- Jul 2019Seed$4M
#4
Seed · Toronto, Ontario · founded 2023$500Kraised▾
AI-powered clinical trial management platform designed to streamline and accelerate Phase I–III studies. It integrates electronic data capture (EDC), eSource, document management (eTMF/ISF), and real-time analytics into a unified system, helping sponsors and CROs reduce manual effort, improve data accuracy, and accelerate study timelines.
- Sep 2025Seed$500K
#5
Series D · Toronto, Ontario · founded 2015 · 426 employees$170Mraised▾
Developer of an AI platform for understanding disease biology. The platform integrates scientific data, including publications, multi-omics, and clinical trials, to provide a unified view of diseases. It combines a Biological Evidence Knowledge Graph with foundation models. The platform offers solutions like AI copilots and co-scientists that accelerate discovery. It ingests internal data to create a customized map of disease biology.
- May 2023Series D$70M
- Jan 2022Series C$50M
- Feb 2020Series B$22M
- Jun 2019Series A$5.1M
#6
Series C · Toronto, Ontario · founded 2014 · 105 employees$238Mraised▾
AI-powered platform for RNA biology to accelerate genetic therapy discovery. It focuses on untangling complex RNA data to identify novel targets and therapeutic candidates for genetic conditions. Its offers proprietary AI platform including the flagship model BigRNA that uses machine learning to analyze vast RNA biology data, identify therapeutic targets, and evaluate potential therapeutic candidates efficiently than traditional approaches. The technology helps accelerate early stages of drug discovery and design of RNA-based therapies.
- Jul 2021Series C$180M
- Jan 2020Series B$40M
- Sep 2017Series A$13M
- Nov 2015Seed$5M
#7
Acquired · Toronto, Ontario · founded 2013 · 56 employees$21.1Mraised▾
AI platform for supporting drug discovery research. The platform focuses on helping teams explore and analyze biological and chemical data to support early stage discovery work. It enables structured investigation and insight generation to aid research decisions within healthcare focused development workflows.
- Nov 2022Grant (prize money)$1.8M
- Apr 2020Series B$16.6M
- Jul 2017Series A$2.2M
- Sep 2016Series A$1.8M
#8
Public · Toronto, Ontario · founded 2020$7.9Mraised▾
Provider of AI-based platform for repurposing psychedelic drugs. The company offers its product PanaceAI, which uses multiple databases and AI to discover novel psychedelic-based drugs. The company has a product pipeline engine for psychedelic-derived drugs and a patent for PanaceAI and certain neurological disorders such as traumatic brain injury, migraines, and rare pediatric disorders.
- Sep 2021Post IPO$7.9M
#9
Seed · Toronto, Ontario · founded 2017 · 32 employees$8Mraised▾
Developer of deep learning based tools for drug discovery. The company leverages AI and machine learning for oncology drug discovery, particularly targeting the tumor stroma in hard-to-treat solid tumors like colorectal, pancreatic, and breast cancers.
- Oct 2020Seed$6M
- Jun 2018Seed$1M
- 2017Seed$500K
#10
Funding Raised · Toronto, Ontario · founded 2006 · 17 employees$10Mraised▾
Pathcore Web is a secure, browser-based platform for managing your digital pathology and radiology images. Research teams can create, analyze, and share cases anywhere, at any time. Its custom metadata system allows for comprehensive analysis and reporting. It allows to assign roles and permissions to users, email links to collaborators, and anonymize data, all with a single click. They also provide a product called Sedeen which supports a variety of whole slide image formats. It currently supports Aperio SVS, Leica SCN, other TIFF-based formats, and JPEG-2000 images
- Mar 2016Grant (prize money)$3.1M
- Mar 2016Grant (prize money)$4M
- Jan 2016Grant (prize money)$2.9M
- Jan 2015Grant (prize money)—
#11
Seed · Toronto, Ontario · founded 2017 · 9 employees$189Kraised▾
AI-based clinical image analysis and reporting tool. The company has developed software that assists with the clinical-pathological diagnosis of diseases. It has features for speech recognization, video image analysis, AI-based disease detection, and more.
- Aug 2023Seed$189K
#12
Seed · Toronto, Ontario · founded 2015 · 6 employees$1.3Mraised▾
Ranomics is building a database of rare genetic variants. It uses a wet lab experimental pipeline to map all genetic variants and catalogs the functionality of each variant using data modeling and statistical analysis, which can then be accessed from a secure database. Currently, it has mapped all variants of the BRCA gene and is completing it for three more genes: TP53, CHEK2, and CDK4.
- Sep 2016Seed$1.2M
- Feb 2015Seed$100K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Toronto is moving
A read on the academic research around Biotechnology in Toronto — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 63 papers.
- University of Toronto61
- Toronto General Hospital2
- Toronto Centre for Phenogenomics1
- Toronto Metropolitan University1
- Genome2
- Cancer research2
- Transcription factor2
- Mutant2
- RNA-binding protein2
- Virus4
- Cell4
- Cell culture3
- Gene3
- HeLa2
- Nanoparticle3
- In vivo3
- Nanotechnology2
- Biodistribution2
- Toxicity2
Who's building biotechnology IP in Toronto
- ls travel retail north america4toronto
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.